Zydus Lifesciences Limited announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg, via an exchange filing.
Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Canagliflozin Tablets had annual sales of USD 660 mn in the United States (IQVIA MAT Dec. 2022).
FPJ Impact: SRA Orders All 13 Sub-Departments To Submit RTI Data After SIC Misreporting In 18th Annual Report
Versova-Dahisar Coastal Road Is 'Ecological Suicide, Not Progress': Mumbai Activist Warns CM, BMC, MoEF On Mangrove Destruction
Bombay HC Allows Capital Gains Tax Exemption For Multiple Homes Under Pre-2015 Law
Bombay HC Dismisses Plea Challenging Redevelopment Of ₹20,000 Crore Goregaon's Motilal Nagar Through Adani Realty
The group now has 341 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
